-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, Roche announced the positive results of the company's CD20 antibody Ocrevus (ocrelizumab) in the treatment of patients with early multiple sclerosis (MS).
The interim data analysis of the open-label Phase 3b clinical trial ENSEMBLE showed that 85% of patients with early relapsing-remitting multiple sclerosis (RRMS) had not shown any signs of disease progression after receiving Ocrevus for 48 weeks.
Multiple sclerosis (MS) is a chronic autoimmune disease caused by the immune system attacking the myelin sheath that protects nerves.
The progression of MS leads to a decline in physical functions (such as walking) and cognitive functions (such as memory).
There are three main types of MS: relapsing-remitting MS, secondary progressive MS (SPMS) and primary progressive MS (PPMS).
Relapsing-remitting MS is characterized by a well-defined relapse and remission process, that is, relapse, onset or deterioration, followed by a partial or complete recovery period, during which the symptoms are partially or completely improved without significant disease deterioration.
However, as the number of relapses increases, most patients' condition will gradually get worse.
There are more than 2.
8 million MS patients worldwide, and it is one of the leading causes of non-traumatic disability in young people.
Most patients have their first symptoms between the ages of 20-40.
Ocrevus is a humanized monoclonal antibody targeting CD20 positive B cells.
This cell is believed to be a key factor in causing damage to the myelin sheath and nerve cell axons.
By combining with CD20 on the surface of B cells, it can achieve the effect of removing B cells from the blood circulation.
Ocrevus can specifically bind to the CD20 protein expressed on the surface of some B cells, but will not bind to the CD20 protein on the surface of stem cells or plasma cells, so it can retain important functions of the immune system.
In the phase 3 clinical trial called ENSEMBLE, patients who were newly diagnosed and had not yet received pre-disease modification therapy (DMT) received Ocrevus treatment.
The interim analysis showed that after 48 weeks of treatment, 85% of patients showed no signs of disease activity (including no disease recurrence, no aggravation of disability, and MRI imaging showed no new or expanded brain lesions).
In all patients, the annual recurrence rate was 0.
005.
In addition, the level of nerve fiber light chain (NfL), a biomarker of nerve cell damage, decreased to a level similar to that of healthy people.
The baseline level in the Ocrevus group was 10.
5 pg/mL, which decreased to 4.
55 pg/mL at 48 weeks after receiving treatment, and the value in the healthy control group was 4.
12 pg/mL.
"All MS patients, regardless of the type of disease they have, will experience disease progression.
So these latest analysis results are encouraging to us, and it shows that Ocrevus can significantly control the progression of the
disease .
Controlling the progression of the disease allows MS patients to maintain their
Mobility and control of their disability.
” said Dr.
Levi Garraway, Roche’s chief medical officer and head of global product development, “Moreover, Ocrevus only requires patients to receive treatment twice a year.
Our data shows that this allows more patients to continue to receive treatment.
, Thereby improving the prognosis of patients. "Related reading: From rapid diagnosis to precise treatment, open the way to coexist with the disease | Multiple Sclerosis Forum Essence In 10-20 years, what other key successes will we achieve? | Multiple Sclerosis Forum Essence Reference Materials: [1] New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis.
Retrieved April 16, 2021, from 16.
htm Note: This article is intended to introduce the progress of medical and health research, not a recommendation
for a treatment plan .
If you need guidance on a treatment plan, please go to a regular hospital for treatment.
The interim data analysis of the open-label Phase 3b clinical trial ENSEMBLE showed that 85% of patients with early relapsing-remitting multiple sclerosis (RRMS) had not shown any signs of disease progression after receiving Ocrevus for 48 weeks.
Multiple sclerosis (MS) is a chronic autoimmune disease caused by the immune system attacking the myelin sheath that protects nerves.
The progression of MS leads to a decline in physical functions (such as walking) and cognitive functions (such as memory).
There are three main types of MS: relapsing-remitting MS, secondary progressive MS (SPMS) and primary progressive MS (PPMS).
Relapsing-remitting MS is characterized by a well-defined relapse and remission process, that is, relapse, onset or deterioration, followed by a partial or complete recovery period, during which the symptoms are partially or completely improved without significant disease deterioration.
However, as the number of relapses increases, most patients' condition will gradually get worse.
There are more than 2.
8 million MS patients worldwide, and it is one of the leading causes of non-traumatic disability in young people.
Most patients have their first symptoms between the ages of 20-40.
Ocrevus is a humanized monoclonal antibody targeting CD20 positive B cells.
This cell is believed to be a key factor in causing damage to the myelin sheath and nerve cell axons.
By combining with CD20 on the surface of B cells, it can achieve the effect of removing B cells from the blood circulation.
Ocrevus can specifically bind to the CD20 protein expressed on the surface of some B cells, but will not bind to the CD20 protein on the surface of stem cells or plasma cells, so it can retain important functions of the immune system.
In the phase 3 clinical trial called ENSEMBLE, patients who were newly diagnosed and had not yet received pre-disease modification therapy (DMT) received Ocrevus treatment.
The interim analysis showed that after 48 weeks of treatment, 85% of patients showed no signs of disease activity (including no disease recurrence, no aggravation of disability, and MRI imaging showed no new or expanded brain lesions).
In all patients, the annual recurrence rate was 0.
005.
In addition, the level of nerve fiber light chain (NfL), a biomarker of nerve cell damage, decreased to a level similar to that of healthy people.
The baseline level in the Ocrevus group was 10.
5 pg/mL, which decreased to 4.
55 pg/mL at 48 weeks after receiving treatment, and the value in the healthy control group was 4.
12 pg/mL.
"All MS patients, regardless of the type of disease they have, will experience disease progression.
So these latest analysis results are encouraging to us, and it shows that Ocrevus can significantly control the progression of the
disease .
Controlling the progression of the disease allows MS patients to maintain their
Mobility and control of their disability.
” said Dr.
Levi Garraway, Roche’s chief medical officer and head of global product development, “Moreover, Ocrevus only requires patients to receive treatment twice a year.
Our data shows that this allows more patients to continue to receive treatment.
, Thereby improving the prognosis of patients. "Related reading: From rapid diagnosis to precise treatment, open the way to coexist with the disease | Multiple Sclerosis Forum Essence In 10-20 years, what other key successes will we achieve? | Multiple Sclerosis Forum Essence Reference Materials: [1] New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis.
Retrieved April 16, 2021, from 16.
htm Note: This article is intended to introduce the progress of medical and health research, not a recommendation
for a treatment plan .
If you need guidance on a treatment plan, please go to a regular hospital for treatment.
